Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anne Lok
Observed names:
A Lok,
A. Lok,
Lok, Anne
Institutions:
Centre Hospitalier Universitaire de Nantes,
Nantes Université
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Centre Hospitalier Universitaire de Nantes,
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers,
Centre Hospitalier de la Côte Basque,
Université de Nantes,
Université d'Angers,
Nantes Université
show all 8
ORCID:
0000-0001-8340-0963
Observed ORCID:
0000-0001-8340-0963
OpenAlex ID:
A5085813390
p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell
2017
·
B Tessoulin
, M Eveillard
, et al.
·
Blood Reviews
·
60
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
2024
·
Patrice Chevallier
, Thibaut Leguay
, et al.
·
Journal of Clinical Oncology
·
56
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study
2015
·
A. Lassalle
, P. Thomaré
, et al.
·
Annals of Oncology
·
53
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
2020
·
Clara Sortais
, Anne Lok
, et al.
·
Annals of Hematology
·
52
Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
2021
·
Patrice Chevallier
, Marianne Coste‐Burel
, et al.
·
eJHaem
·
36
PDF
p53 regulates CD46 expression and measles virus infection in myeloma cells
2018
·
Anne Lok
, Geraldine Descamps
, et al.
·
Blood Advances
·
35
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
2019
·
Maxime Jullien
, Sabrina Trudel
, et al.
·
Annals of Hematology
·
34
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy
2021
·
Thomas Gastinne
, Amandine Le Bourgeois
, et al.
·
British Journal of Haematology
·
33
PDF
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
2021
·
Amandine Le Bourgeois
, Marianne Coste‐Burel
, et al.
·
British Journal of Haematology
·
26
PDF
The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
2019
·
Lina Benaniba
, Benoit Tessoulin
, et al.
·
BMC Cancer
·
21
PDF
A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
2020
·
Pierre Peterlin
, Joelle Gaschet
, et al.
·
Cancer Medicine
·
19
PDF
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
2019
·
Sabrina Trudel
, Benoît Tessoulin
, et al.
·
Annals of Hematology
·
19
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
2018
·
Patrice Chevallier
, Pierre Peterlin
, et al.
·
Oncotarget
·
19
PDF
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma
2014
·
A. Lok
, J. Mocquard
, et al.
·
Haematologica
·
18
PDF
Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma
2016
·
S Wuillème
, A Lok
, et al.
·
Bone Marrow Transplantation
·
17
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
2022
·
Maxime Jullien
, Amandine Le Bourgeois
, et al.
·
Transplantation and Cellular Therapy
·
16
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience
2020
·
Vanille Laurent
, Clémentine Fronteau
, et al.
·
Bone Marrow Transplantation
·
15
FLT3 ligand plasma levels in acute myeloid leukemia
2019
·
Pierre Peterlin
, Joelle Gaschet
, et al.
·
Haematologica
·
15
PDF
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas
2017
·
B. Tessoulin
, P. Thomare
, et al.
·
Annals of Hematology
·
14
Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies
2025
·
Bénédicte Piron
, Laura Rodrigo
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
12
PDF
Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide
2020
·
Patrice Chevallier
, Ana Berceanu
, et al.
·
Acta Oncologica
·
9
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide
2020
·
Alice Garnier
, Thierry Guillaume
, et al.
·
Annals of Hematology
·
9
Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T ‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
2024
·
Maxime Jullien
, Thierry Guillaume
, et al.
·
American Journal of Hematology
·
7
PDF
Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients
2018
·
Louise Bouard
, Caroline Bodet-Milin
, et al.
·
Transplantation and Cellular Therapy
·
5
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
2019
·
Louise Bouard
, Thierry Guillaume
, et al.
·
Transplantation and Cellular Therapy
·
4
Show more works
View as search
Works count:
59
Citation count:
628
H-index:
16
I10-index:
20
Year
Topic
Type